Plain-English translation of NCT07533955 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called , which is given as a subcutaneous injection (a shot just under the skin), for people with rheumatoid arthritis. Researchers want to understand how safe the medication is, how well people tolerate it, and how the body processes it. This information will help decide whether this treatment is worth studying further.
Rheumatoid arthritis is a serious autoimmune condition, and doctors are always looking for new treatment options that might work better or with fewer side effects for their patients. This trial is the first step in testing whether this new medication could become a useful option for people with this disease.
You likely qualify if…
You likely don't qualify if…
You would receive either the new medication or a placebo (inactive injection) as a subcutaneous shot. The study involves an inpatient stay at the research site and several scheduled visits where researchers will monitor your safety with blood tests and other procedures. Your main responsibility is to follow the study schedule closely, stay for the required time at the site, and report any side effects or concerns you experience.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Moldova
Ukraine
Phase
Safety & dosing
Sponsor
Jade Biosciences, Inc.
Enrollment target
~36 participants
Started
May 2026
Primary completion
October 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jade201 Study Contact
Jade Biosciences, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.